MicroRNA-873 Mediates Multidrug Resistance in Ovarian Cancer Cells by Targeting ABCB1

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2016 Feb 7

PMID 26850595

Citations 38

Authors

Di-di Wu

Xue-Song Li

Xiao-Na Meng

Jing Yan

Zhi-Hong Zong

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is commonly treated with cisplatin and paclitaxel combination chemotherapy; however, ovarian cancer cells often develop resistance to these drugs. Increasingly, microRNAs (miRNAs) including miR-873 have been implicated in drug resistance in many cancers, but the role of miR-873 in ovarian cancer remains unknown. MTT cell viability assays revealed that the sensitivities of ovarian cancer lines to cisplatin and paclitaxel increased following transfection with miR-873 (P < 0.05). After predicting the miR-873 binding region in the 3'-untranslated region of ABCB1, dual-luciferase reporter assay confirmed this prediction. RT-PCR and Western blotting revealed that MDR1 expression was significantly downregulated after transfection with miR-873 and upregulated after transfection with anti-miR-873 at both mRNA and protein levels compared to negative controls (P < 0.05). Experiments in a mouse xenograft model confirmed that intratumoral administration of miR-873 could enhance the efficacy of cisplatin in inhibiting tumor growth in ovarian cancer in vivo (P < 0.05). ABCB1 overexpression reduced sensitivities of ovarian cancer lines OVCAR3 and A2780 to cisplatin and paclitaxel, which can be reversed by miR-873 mimic transfection (P < 0.05). In summary, we demonstrated that overexpression of miR-873 increased the sensitivity of ovarian cancer cells to cisplatin and paclitaxel by targeting MDR1 expression. Our findings suggest that combination therapies with chemotherapy agents and miR-873 may suppress drug resistance in ovarian cancer.

Citing Articles

MicroRNA‑mediated approaches in ovarian cancer therapy: A comprehensive systematic review.

Putri H, Novianti P, Pradjatmo H, Haryana S Oncol Lett. 2024; 28(4):491.

PMID: 39185494 PMC: 11342411. DOI: 10.3892/ol.2024.14624.

MiR-125b targeted regulation of MKNK2 inhibits multiple myeloma proliferation and invasion.

Tan B, Yang G, Su L, Zhou J, Wu Y, Liang C Am J Transl Res. 2024; 16(7):3366-3375.

PMID: 39114709 PMC: 11301515. DOI: 10.62347/QWGS2351.

Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors.

Alam S, Giri P Cancer Drug Resist. 2024; 7:6.

PMID: 38434767 PMC: 10905178. DOI: 10.20517/cdr.2023.152.

Nucleic acid vaccination strategies for ovarian cancer.

Saha C, Bojdo J, Dunne N, Duary R, Buckley N, McCarthy H Front Bioeng Biotechnol. 2022; 10:953887.

PMID: 36420446 PMC: 9677957. DOI: 10.3389/fbioe.2022.953887.

The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer.

Wang Y, Huang Z, Li B, Liu L, Huang C Front Endocrinol (Lausanne). 2022; 13:863541.

PMID: 35620395 PMC: 9127157. DOI: 10.3389/fendo.2022.863541.

References

Yang L, Trujillo J, Siciliano M, Kido Y, Siddik Z, Su Y . Distinct P-glycoprotein expression in two subclones simultaneously selected from a human colon carcinoma cell line by cis-diamminedichloroplatinum (II). Int J Cancer. 1993; 53(3):478-85. DOI: 10.1002/ijc.2910530321. View

Zhao M, Lei C, Yang Y, Bu X, Ma H, Gong H . Abraxane, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gp. PLoS One. 2015; 10(7):e0131429. PMC: 4504487. DOI: 10.1371/journal.pone.0131429. View

Deng H, Lv L, Li Y, Zhang C, Meng F, Pu Y . miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the oxidative stress pathway. Mol Cancer. 2014; 13:234. PMC: 4200202. DOI: 10.1186/1476-4598-13-234. View

Xu H, Choi S, An C, Min Y, Kim K, Kim K . Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines. Biochem Biophys Res Commun. 2005; 328(2):618-22. DOI: 10.1016/j.bbrc.2005.01.015. View

Feng D, Zhang H, Zhang P, Zheng Y, Zhang X, Han B . Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med. 2010; 15(10):2164-75. PMC: 4394226. DOI: 10.1111/j.1582-4934.2010.01213.x. View

Zhu X, Li Y, Shen H, Li H, Long L, Hui L . miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1. Acta Biochim Biophys Sin (Shanghai). 2012; 45(2):80-6. DOI: 10.1093/abbs/gms099. View

Liu Y, Xia X, Zhou M, Liu X . Avastin® in combination with gemcitabine and cisplatin significantly inhibits tumor angiogenesis and increases the survival rate of human A549 tumor-bearing mice. Exp Ther Med. 2015; 9(6):2180-2184. PMC: 4473346. DOI: 10.3892/etm.2015.2402. View

Hamaguchi K, Godwin A, Yakushiji M, ODwyer P, Ozols R, Hamilton T . Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res. 1993; 53(21):5225-32. View

Cui L, Zhou H, Zhao H, Zhou Y, Xu R, Xu X . MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. BMC Cancer. 2012; 12:546. PMC: 3518250. DOI: 10.1186/1471-2407-12-546. View

10.

Sparreboom A, Scripture C, Trieu V, Williams P, De T, Yang A . Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res. 2005; 11(11):4136-43. DOI: 10.1158/1078-0432.CCR-04-2291. View

11.

Zhou S . Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica. 2008; 38(7-8):802-32. DOI: 10.1080/00498250701867889. View

12.

Vallo S, Michaelis M, Rothweiler F, Bartsch G, Gust K, Limbart D . Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics. Transl Oncol. 2015; 8(3):210-6. PMC: 4487788. DOI: 10.1016/j.tranon.2015.04.002. View

13.

Chen X, Zhang Y, Shi Y, Lian H, Tu H, Han S . MiR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2. Int J Oncol. 2015; 47(4):1603-11. DOI: 10.3892/ijo.2015.3143. View

14.

Wang R, Li J, Bao B, Wu H, Du Z, Su J . MicroRNA-873 (miRNA-873) inhibits glioblastoma tumorigenesis and metastasis by suppressing the expression of IGF2BP1. J Biol Chem. 2015; 290(14):8938-48. PMC: 4423684. DOI: 10.1074/jbc.M114.624700. View

15.

Dai F, Zhang Y, Zhu X, Shan N, Chen Y . The anti-chemoresistant effect and mechanism of MUC1 aptamer-miR-29b chimera in ovarian cancer. Gynecol Oncol. 2013; 131(2):451-9. DOI: 10.1016/j.ygyno.2013.07.112. View

16.

Zhu X, Wu L, Yao J, Jiang H, Wang Q, Yang Z . MicroRNA let-7c Inhibits Cell Proliferation and Induces Cell Cycle Arrest by Targeting CDC25A in Human Hepatocellular Carcinoma. PLoS One. 2015; 10(4):e0124266. PMC: 4409336. DOI: 10.1371/journal.pone.0124266. View

17.

Kumar S, Kumar A, Shah P, Rai S, Panguluri S, Kakar S . MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res. 2011; 4(1):17. PMC: 3205057. DOI: 10.1186/1757-2215-4-17. View

18.

Gisel A, Valvano M, Ghafir El Idrissi I, Nardulli P, Azzariti A, Carrieri A . miRNAs for the detection of multidrug resistance: overview and perspectives. Molecules. 2014; 19(5):5611-23. PMC: 6270919. DOI: 10.3390/molecules19055611. View

19.

Chen S, Jiao J, Sun K, Zong Z, Zhao Y . MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Drug Des Devel Ther. 2015; 9:5225-35. PMC: 4577257. DOI: 10.2147/DDDT.S87526. View

20.

Haenisch S, Werk A, Cascorbi I . MicroRNAs and their relevance to ABC transporters. Br J Clin Pharmacol. 2014; 77(4):587-96. PMC: 3971975. DOI: 10.1111/bcp.12251. View